Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075758 | 0.86 | PKM (0.63) | ALDH1A1HTTPOLBLMNATSHR | |
| SCHEMBL29830772 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HTTPOLBLMNACYP3A4 | |
| SCHEMBL10702111 | 0.85 | LMNA (0.56) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL7080668 | 0.84 | MEN1 (0.54) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL7082412 | 0.84 | LMNA (0.53) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL7080360 | 0.84 | LMNA (0.52) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL7109414 | 0.83 | LMNA (0.51) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL19011426 | 0.82 | LMNA (0.66) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL7079622 | 0.81 | HTR1A (0.55) | ALDH1A1HTTPOLBLMNAMEN1 | |
| SCHEMBL10798902 | 0.80 | LMNA (0.64) | ALDH1A1HTTPOLBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | ALDH1A1 3435/4885HTT 3632/4885POLB 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.